New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 20, 2014
08:03 EDTIG, IPXLIGI Laboratories completes seventh ANDA filing under joint agreement with Impax
IGI Laboratories (IG) announced it has submitted its seventh abbreviated new drug application in 2014 to the FDA. The seventh ANDA submission was in connection with an existing development, supply and marketing agreement with Impax Laboratories (IPXL). The agreement designates IGI Laboratories as the developer, manufacturer, and owner of a generic topical pharmaceutical drug product, which will be licensed, marketed and distributed in the United States by Global Pharmaceuticals, Impax's generics division. In accordance with the agreement, Impax is required to pay IGI when certain milestones are met related to the filing and approval of the associated ANDA.
News For IG;IPXL From The Last 14 Days
Check below for free stories on IG;IPXL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 8, 2014
09:23 EDTIGIGI Laboratories price target raised to $9 from $7.25 at Roth Capital
Subscribe for More Information
September 5, 2014
20:38 EDTIGIGI Laboratories management to meet with Craig-Hallum
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use